【华泰证券】FY22业绩不及预期；零售能力强化.pdf

FY22E preview; Bumpy recovery in 2023

华润医药：1H22业绩巩固了FY22E的正面

石四药集团：强劲的1H22结果；但FY22E指引略低

Resilient FY22／1H23 despite industry headwinds

FY22 net margins better than expected

Outperforming FY22E, promising FY23E and not-far-fetching FY25E target

IMAX China(01970)FY22业绩会纪要-港股20230223-调研纪要

遥望科技(002291)FY22&1Q23业绩交流会-调研纪要

Yanlord：Resilient FY22 results and business model; maintain Buy

Hopson： weaker but much better than peers FY22